Other languages Protara Therapeutics, Inc.

Equities

TARA

US74365U1079

Real-time Estimate Cboe BZX Other stock markets 11:32:44 2024-04-29 am EDT			5-day change	1st Jan Change
2.91 ^USD	-0.51%		-0.16%	+62.39%

Apr. 22	Oppenheimer Adjusts Protara Therapeutics Price Target to $30 From $26	MT
Apr. 05	Protara Therapeutics, Inc Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Protara Therapeutics, Inc Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition	Apr. 05
Protara Therapeutics, Inc. Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC	Apr. 05
Protara Therapeutics, Inc. Announces Resignation of Jathin Bandari as Chief Medical Officer, Effective April 11, 2024	Mar. 18
Protara Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 13
Protara Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 13
Proteon Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 13
Top Premarket Gainers	Mar. 12
Top Premarket Decliners	Feb. 12
Top Premarket Decliners	Jan. 17
Protara Therapeutics Says 5 of 6 Patients in Dose Escalation Portion of Bladder Cancer Trial Showed Recurrence-Free Survival	Nov. 30
Protara Therapeutics, Inc. Announces Presentation of Additional Encouraging Data from Phase 1A Advanced-1 Trial of Tara-002 in Nmibc At the 24Th Annual Meeting of the Society of Urologic Oncology	Nov. 30
Protara Therapeutics Q3 Loss Widens; Files for $300 Million Mixed-Securities Shelf Registration	Nov. 03
Protara Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 03
Proteon Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 03
Protara Therapeutics Doses First Patient in Phase 1b/2 Bladder Cancer Trial; Shares Rise	23-09-20
Protara Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03
Proteon Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03
Protara Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04
Protara Therapeutics Receives Regulatory Clearance from FDA to Commence Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations	23-05-02
Protara Therapeutics Reports Positive Results From Portion of TARA-002 Trial to Treat Bladder Cancer; Shares Rise	23-04-28

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Protara Therapeutics, Inc.

Equities

TARA

US74365U1079

Other languages

Filters